Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

41. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine (Abstract)

Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine The objective of this paper is to better understand the relationship of pain and mood in patients with fibromyalgia and comorbid major depressive disorder (MDD). Pooled data from 4 double-blind, placebo-controlled, randomized trials of duloxetine hydrochloride 60-120mg/day in patients with fibromyalgia were included (...) (N=1332). Of these, 350 (26% [147 placebo, 203 duloxetine]) had comorbid MDD (per Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria) and were included in these analyses. Primary measures included Brief Pain Inventory average pain; Hamilton Depression Rating Scale or Beck Depression Inventory. Logistic regression was used to evaluate the consistency of treatment effect across various subgroups. Path analysis was used to assess the effect of duloxetine

2011 EvidenceUpdates

42. Pain response profile of patients with fibromyalgia treated with duloxetine (Abstract)

Pain response profile of patients with fibromyalgia treated with duloxetine This study examined the time course for minimal clinically significant improvement in pain severity during the initial 12 weeks of treatment in patients with fibromyalgia taking duloxetine.Four double-blind, placebo-controlled trials of duloxetine were pooled. Patients received duloxetine 60 mg/d, 120 mg/d, or placebo. Clinically significant treatment response (>or=30% reduction in pain severity on the 24-hour average (...) pain severity of the Brief Pain Inventory scale) was assessed over 12 weeks.At endpoint, 46.9% of duloxetine 60-mg-, 48.6% of duloxetine 120-mg-, and 32.1% of placebo-treated patients (P<0.001 for both doses) had >or=30% improvement on average pain from baseline. The probabilities of achieving >or=30% response at Weeks 1, 2, 4, 8, and 12 among duloxetine 60-mg-treated patients were 27%, 44%, 45%, 47%, and 49%, respectively, and among duloxetine 120-mg-treated patients were 35%, 43%, 53%, 53

2010 EvidenceUpdates Controlled trial quality: uncertain

43. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome (Abstract)

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Duloxetine (DLX), milnacipran (MLN), and pregabalin (PGB) are the only drugs licensed by the US Food and Drug Administration (FDA) for fibromyalgia syndrome (FMS). Evidence on the comparative benefits and harms is still accruing. The authors searched MEDLINE, SCOPUS, Cochrane Central Register of Controlled Trials, and sought unpublished data from the databases of FDA, US National Institutes (...) ) efficacy of DLX, MLN, and PGB. Differences with regard to the occurrence of the key symptoms of FMS and to drug-specific adverse events may be relevant for the choice of medication.This article presents comparative data on the efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. The results can help clinicians in choosing medication since the 3 drugs have different effects on the key symptoms of fibromyalgia syndrome and differences in side effects, contraindications

2010 EvidenceUpdates

44. Cymbalta (duloxetine hydrochloride)

Cymbalta (duloxetine hydrochloride) Drug Approval Package: Cymbalta (duloxetine hydrochloride) NDA #022516 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Cymbalta (duloxetine hydrochloride), 20, 30, and 60 mg Capsules Company: Eli Lilly and Company Application No.: 022516 Approval Date: 11/04/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

45. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Benedict A, Arellano J, De Cock E, Baird J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-utility of duloxetine, compared with selective serotonin re-uptake inhibitors (SSRIs), venlafaxine extended release, and mirtazapine, for the treatment of major

2010 NHS Economic Evaluation Database.

46. Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence

Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Jacklin P, Duckett J, Renganathan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of duloxetine versus tension-free vaginal tape as the second-line treatment for urinary stress incontinence, using new data on drug discontinuation rates. The authors concluded that tension-free vaginal tape was more cost-effective than duloxetine and was below the recommended

2010 NHS Economic Evaluation Database.

47. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

48. Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Full Text available with Trip Pro

Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Mihaylova B, Pitman R, Tincello D, van der Vaart H, Tunn R, Timlin L, Quail D, Johns A, Sculpher M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of duloxetine compared with conservative therapy for women with stress urinary incontinence. The authors concluded that, although there were limitations due to the use of observational data, duloxetine therapy seemed to be cost-effective. The methods were good

2010 NHS Economic Evaluation Database.

49. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Del Casale A, Tatarelli R, Baldessarini RJ CRD (...) summary The review found that duloxetine appeared more effective than placebo for acute major depression in adults, and was comparable to selective serotonin-reuptake inhibitors, but that more research is needed. In view of poor reporting of review methods and adverse event outcomes, and lack of statistical evidence that the trials were suitable for pooling, the authors’ conclusions may not be reliable. Authors' objectives To evaluate the efficacy and tolerability of duloxetine for acute major

2009 DARE.

50. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

51. Duloxetine hydrochloride - Neuropathic pain, Diabetic

Duloxetine hydrochloride - Neuropathic pain, Diabetic Common Drug Review CEDAC Meeting – July 16, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – August 14, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DULOXETINE (Cymbalta ™ – Eli Lilly Canada Inc.) Description: Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the management of diabetic peripheral neuropathic pain. Duloxetine is also approved for the symptomatic relief (...) of major depressive disorder. This submission to the Common Drug Review relates solely to its use in diabetic peripheral neuropathic pain. Dosage Forms: 30 mg and 60 mg delayed-release capsules. The recommended dose is 60 mg daily. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that duloxetine be listed for the treatment of neuropathic pain in diabetic patients who are unresponsive to two adequate courses of less costly alternative agents such as a tricyclic

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

52. Duloxetine hydrochloride - Major Depressive Disorder (MDD)

Duloxetine hydrochloride - Major Depressive Disorder (MDD) Common Drug Review CEDAC Meeting – July 16, 2008 Page 1 of 2 Notice of CEDAC Final Recommendation – August 14, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DULOXETINE (Cymbalta ™ – Eli Lilly Canada Inc.) Description: Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the symptomatic relief of major depressive disorder in adults. Duloxetine is also approved (...) for the management of neuropathic pain associated with diabetic peripheral neuropathy. This submission to the Common Drug Review (CDR) deals only with its use in major depressive disorder. Dosage Forms: 30 mg and 60 mg delayed-release capsules. The recommended dose for depression is 60 mg daily. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that duloxetine not be listed for the treatment of major depressive disorder. Reasons for the Recommendation: 1. There is insufficient

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

53. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial (Abstract)

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial The primary objectives of this study were to assess the efficacy and safety of duloxetine for reducing pain severity in fibromyalgia patients with or without current major depressive disorder. This was a 6-month, multicenter, randomized, double-blind, placebo-controlled study. In total, 520 (...) patients meeting American College of Rheumatology criteria for fibromyalgia were randomly assigned to duloxetine (20 mg/day, 60 mg/day, or 120 mg/day) or placebo, administered once daily, for 6 months (after 3 months, the duloxetine 20-mg/day group titrated to 60 mg/day). The co-primary outcome measures were the Brief Pain Inventory (BPI) average pain severity score and Patient Global Impressions of Improvement (PGI-I) score. Safety was assessed via treatment-emergent adverse events, and changes

2008 EvidenceUpdates Controlled trial quality: predicted high

54. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Wade A G, Fernandez J L, Francois C, Hansen K, Danchenko N, Despiegel N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of escitalopram and duloxetine in the treatment of major depressive disorder (MDD) in the UK. The authors concluded that, from a UK societal perspective, escitalopram led to a reduction in costs and improved clinical outcomes in comparison

2008 NHS Economic Evaluation Database.

55. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

56. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder Armstrong EP, Malone DC, Erder MH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of two branded treatments for major depressive disorder. The authors concluded that escitalopram was more effective and less costly than duloxetine. The methodology appears to have been appropriate and, on the whole, was clearly and transparently reported. The conclusions

2008 NHS Economic Evaluation Database.

57. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Full Text available with Trip Pro

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Beard S M, McCrink L, Le T K, Garcia-Cebrian A, Monz B, Malik R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the six-month costs and health benefits of using duloxetine as an additional treatment to the recommended current practice, in the UK, in diabetic patients experiencing peripheral neuropathic pain. The authors concluded that second-line duloxetine created potential cost-savings to the health system

2008 NHS Economic Evaluation Database.

58. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training

Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

59. An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence

An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence Das Gupta R, Caiado M, Bamber L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared five different options for the treatment of moderate-to-severe stress urinary incontinence (SUI). The options compared were: current standard treatment in the authors' setting; duloxetine alone as first-line treatment; duloxetine

2006 NHS Economic Evaluation Database.

60. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.